Needham Starts Clover Health at Buy, $6 Target; Shares Rise 4%

Needham launched Clover Health (CLOV) with a Buy rating and $6 target, citing cohort economics, Clover Assistant and a five-star PPO rating; shares rose 4% Wednesday.